GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... planning launches for five major new product approval opportunities next ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac (CVAC) said: “The third quarter was truly ...

a novel GSK-3β inhibitor for treatment of Ewing sarcoma (EWS). “Receiving rare pediatric disease designation from the FDA underscores the urgent need for new treatment options for patients with EWS ...

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...

CureVac NV (CVAC) reports robust revenue growth and strategic advancements in oncology, despite ongoing litigation challenges.

Commenting on his new mandate, Danny Advani, Head - Business Strategy and Planning, Dot Media said, “Dot Media has ...

PFG Investments LLC lifted its position in GSK plc (NYSE:GSK – Free Report) by 8.5% in the 3rd quarter, Holdings Channel.com ...